Efficacy and safety of pegfilgrastim biosimilar MD‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III

INTRODUCTION: Pegfilgrastim is indicated to decrease the incidence of chemotherapy‐induced febrile neutropenia. It is the first granulocyte‐colony stimulating factor approved for prophylactic use regardless of carcinoma type and is marketed in Japan as G‐LASTA (Kyowa Kirin Co., Ltd., Tokyo, Japan)....

Descripción completa

Detalles Bibliográficos
Autores principales: Takano, Toshimi, Ito, Mitsuya, Kadoya, Takayuki, Osako, Tomofumi, Aruga, Tomoyuki, Masuda, Norikazu, Miyaki, Toshiko, Niikura, Naoki, Shimizu, Daisuke, Yokoyama, Yuichi, Watanabe, Manabu, Tomomitsu, Masato, Aogi, Kenjiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652341/
https://www.ncbi.nlm.nih.gov/pubmed/37824431
http://dx.doi.org/10.1002/cam4.6519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652341/
https://www.ncbi.nlm.nih.gov/pubmed/37824431
http://dx.doi.org/10.1002/cam4.6519

Ejemplares similares